• Contact/
  • Home/

  • About
  • Team
  • Portfolio
  • Exit History
  • News

  • About
  • Team
  • Portfolio
  • Exit History
  • News

  • Advent Life Sciences
  • Advent Life Sciences

Page 3 of 25

 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10Next >End >>
18.02.2022 Nalu Medical Inc. Announces $104 Million Equity Financing

Press Release

16.02.2022Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform

Press Release

11.01.2022Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics

Press Release

15.12.2021Artax Biopharma Announces First-in-Human Dosing in Phase 1 Clinical Trial for AX-158, Company’s First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases

Press Release

06.12.2021Amphista Therapeutics Appoints Dr Martin Pass as CDO

Press Release

02.12.2021AviadoBio™ Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform

Press Release

02.12.2021Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO-112 + STING agonist published in Journal for ImmunoTherapy of Cancer

Press Release

15.11.2021Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology

Press Release

12.11.2021Highlight Therapeutics announces positive preliminary results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at SITC

Press Release

01.11.2021Amphista Therapeutics Appoints CBO, Beverley Carr

Press Release



  • Privacy Policy
  • Legal and Regulatory Matters

©2022 Advent Life Sciences